Klaus Georg Parhofer

Klaus Georg Parhofer's AcademicInfluence.com Rankings

Philosophy

#9602

World Rank

#13187

Historical Rank

Logic

#6571

World Rank

#8100

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Klaus Georg Parhofer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Klaus Georg Parhofer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013) (1786)
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). (2006) (1767)
Adipokines and Insulin Resistance (2008) (802)
Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. (2006) (665)
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment (2015) (545)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (2014) (470)
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. (2014) (442)
Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. (2009) (304)
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events (2009) (283)
Pericardial Adipose Tissue Determined by Dual Source CT Is a Risk Factor for Coronary Atherosclerosis (2009) (266)
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. (2014) (262)
Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia (2015) (252)
[Glucagon-like peptide 1 (GLP-1)]. (2007) (218)
Diabetic dyslipidemia. (2014) (198)
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. (2011) (196)
Clinical review on triglycerides (2019) (194)
[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. (2015) (180)
HDL cholesterol: reappraisal of its clinical relevance (2017) (173)
Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study (2014) (170)
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial (2016) (166)
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation (2015) (162)
Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. (1991) (151)
Liquid chromatography tandem-mass spectrometry (LC-MS/MS)--technique and applications in endocrinology. (2007) (138)
Resistin is an inflammatory marker of inflammatory bowel disease in humans (2007) (136)
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. (2001) (135)
Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. (2014) (131)
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. (2011) (116)
Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe (2010) (107)
Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat Diet (2010) (106)
Effects of phytosterol ester-enriched margarine on plasma lipoproteins in mild to moderate hypercholesterolemia are related to basal cholesterol and fat intake. (2002) (103)
Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. (2007) (100)
PROGNOSTIC VALUE OF INTERLEUKIN 6, PROCALCITONIN, AND C-REACTIVE PROTEIN LEVELS IN INTENSIVE CARE UNIT PATIENTS DURING FIRST INCREASE OF FEVER (2006) (99)
ApoB-75, a truncation of apolipoprotein B associated with familial hypobetalipoproteinemia: genetic and kinetic studies. (1992) (93)
The stool microbiota of insulin resistant women with recent gestational diabetes, a high risk group for type 2 diabetes (2015) (90)
The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. (2006) (90)
Diagnostic algorithm for familial chylomicronemia syndrome. (2017) (88)
Lipoproteins containing the truncated apolipoprotein, Apo B-89, are cleared from human plasma more rapidly than Apo B-100-containing lipoproteins in vivo. (1992) (86)
Influence of protease inhibitor therapy on lipoprotein metabolism (1999) (83)
Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. (1999) (83)
Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. (2006) (83)
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text (2007) (82)
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. (2020) (81)
Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? (2014) (78)
Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B. (1995) (77)
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement (2022) (75)
Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. (2000) (75)
Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial. (2014) (73)
[Polycystic ovary syndrome and metabolic syndrome]. (2002) (71)
A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial (2018) (70)
Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes (2017) (68)
Bowel habits and bile acid malabsorption in the months after cholecystectomy (2002) (68)
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) (2021) (68)
Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. (2003) (65)
Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes. (1996) (64)
Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques (2008) (63)
Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort (2009) (63)
Can LDL cholesterol be too low? Possible risks of extremely low levels (2017) (62)
MMP-1 serum levels predict coronary atherosclerosis in humans (2009) (62)
Serum concentrations of cortisol, interleukin 6, leptin and adiponectin predict stress induced insulin resistance in acute inflammatory reactions (2008) (62)
Lipoprotein apheresis to treat elevated lipoprotein (a)1 (2016) (62)
Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). (2010) (60)
Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies Published, JLR Papers in Press, May 23, 2006. (2006) (56)
Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. (2006) (54)
Systemic Cardiovascular Complications in Patients With Long-Standing Diabetes Mellitus: Comprehensive Assessment With Whole-Body Magnetic Resonance Imaging/Magnetic Resonance Angiography (2009) (53)
Cardiac Output Measurements in Septic Patients: Comparing the Accuracy of USCOM to PiCCO (2011) (52)
The Treatment of Disorders of Lipid Metabolism. (2016) (52)
Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients Published, JLR Papers in Press, April 1, 2003. DOI 10.1194/jlr.M300011-JLR200 (2003) (49)
Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease. (2012) (48)
ApoB-54.8, a truncated apolipoprotein found primarily in VLDL, is associated with a nonsense mutation in the apoB gene and hypobetalipoproteinemia. (1991) (48)
Current Role of Lipoprotein Apheresis (2019) (48)
PANORAMA: a European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus--study design. (2011) (48)
Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. (2004) (47)
Long-term reduction of C-reactive protein concentration by regular LDL apheresis. (2004) (47)
Complications and Monitoring – Guidelines on Parenteral Nutrition, Chapter 11 (2009) (47)
Changes in body weight, glucose homeostasis, lipid profiles, and metabolic syndrome after restrictive bariatric surgery. (2012) (46)
Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. (2000) (45)
Enhanced clearance from plasma of low density lipoproteins containing a truncated apolipoprotein, apoB-89. (1990) (45)
The effects of three different LDL‐apheresis methods on the plasma concentrations of E‐selectin, VCAM‐1, and ICAM‐1 (2002) (42)
The Diabetes Risk Phenotype of Young Women With Recent Gestational Diabetes. (2015) (42)
Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. (2015) (41)
Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study (2007) (39)
Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia (2012) (39)
A Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient Replacement and Time Point of Consumption: A Prospective, Randomized, Controlled Trial (2017) (39)
Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure (2019) (38)
Clinically stable very low birthweight infants are at risk for recurrent tissue glucose fluctuations even after fully established enteral nutrition (2014) (38)
Reduced proliferation and a high apoptotic frequency of pancreatic beta cells contribute to genetically-determined diabetes susceptibility of db/db BKS mice. (2011) (37)
Genetic variants of adiponectin receptor 2 are associated with increased adiponectin levels and decreased triglyceride/VLDL levels in patients with metabolic syndrome (2006) (37)
Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort (2017) (37)
Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. (2001) (37)
Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. (2013) (37)
Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment (2011) (37)
Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans (2013) (37)
Efficacy of different low-density lipoprotein apheresis methods. (2000) (36)
Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol. (2020) (35)
Comparison of current guidelines for primary prevention of coronary heart disease (2003) (35)
Diabetes mellitus: long-term prognostic value of whole-body MR imaging for the occurrence of cardiac and cerebrovascular events. (2013) (35)
Association of leptin and insulin with childhood obesity and retinal vessel diameters (2014) (34)
Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial. (2001) (33)
The Diagnosis and Treatment of Hypertriglyceridemia. (2019) (33)
Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study). (2017) (32)
CXCL16 is a surrogate marker of inflammatory bowel disease (2008) (32)
Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia. (1996) (31)
Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study. (2005) (31)
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia (2007) (30)
Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism (2016) (29)
High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-&ggr; Target Genes in Patients With the Metabolic Syndrome (2011) (29)
[Operative techniques and outcomes in metabolic surgery: sleeve gastrectomy]. (2009) (29)
Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. (2006) (29)
Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia (2007) (29)
Contribution of socioeconomic status, stature and birth weight to obesity in Sub-Saharan Africa: cross-sectional data from primary school-age children in Cameroon (2014) (29)
Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia. (2007) (29)
Dextran‐sulfate‐adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid‐apheresis—Comparison of performance characteristics with DALI and lipidfiltration (2007) (28)
Relative roles of the different Pax6 domains for pancreatic alpha cell development (2010) (28)
Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels (2006) (27)
The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease (2013) (26)
In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis. (2004) (26)
Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review (2020) (26)
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary. (2014) (26)
Lipoprotein(a): medical treatment options for an elusive molecule. (2011) (25)
Apolipoprotein A‐IV Is an Independent Predictor of Disease Activity in Patients with Inflammatory Bowel Disease (2007) (24)
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia (2009) (24)
Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. (2002) (24)
Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). (1999) (23)
Hypoglycaemic episodes in patients with type 2 diabetes--risk factors and associations with patient-reported outcomes: The PANORAMA Study. (2015) (23)
Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature. (2009) (23)
Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line (2008) (23)
Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia (1993) (23)
Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). (2019) (23)
Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. (2005) (22)
Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial (2003) (22)
New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk (2014) (21)
Effects of lipoprotein apheresis on PCSK9 levels. (2015) (21)
Mortality of Patients with Hematological Malignancy after Admission to the Intensive Care Unit (2012) (20)
Differences in the Serum Nonesterified Fatty Acid Profile of Young Women Associated with a Recent History of Gestational Diabetes and Overweight/Obesity (2015) (20)
Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. (2018) (20)
Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport (2016) (20)
New approaches to address dyslipidemia (2017) (19)
Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia. (2003) (19)
Prevention Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment (2015) (19)
Malacoplakia in a renal transplant recipient. (2006) (19)
Prevalence and sociodemographic determinants of adult obesity: a large representative household survey in a resource-constrained African setting with double burden of undernutrition and overnutrition (2018) (19)
Effect of sleeve gastrectomy on postprandial lipoprotein metabolism in morbidly obese patients (2013) (17)
Lipoprotein (a) metabolism estimated by nonsteady-state kinetics (1999) (17)
PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice (2019) (17)
Effects of Ursodeoxycholic Acid on Synthesis of Cholesterol and Bile Acids in Healthy Subjects (2004) (16)
Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B. (2000) (16)
Prognostic parameters and risk stratification in intensive care patients with severe liver diseases. (2010) (16)
Predictors of glucose control in children and adolescents with type 1 diabetes: results of a cross-sectional study in Cameroon (2017) (15)
Height-obesity relationship in school children in Sub-Saharan Africa: results of a cross-sectional study in Cameroon (2015) (15)
No non-redundant function of suppressor of cytokine signaling 2 in insulin producing β-cells (2010) (14)
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial. (2016) (14)
Whole-Body MR Imaging Including Angiography: Predicting Recurrent Events in Diabetics (2015) (13)
Effect of a high-fat meal on the postprandial ghrelin response. (2006) (13)
Prevalence of Cardiovascular Disease Risk Factors in Migrants Participating in the PEP Family Heart Study, Nuremberg (2010) (12)
Limited preanalytical requirements for insulin measurement. (2005) (12)
Low-density lipoprotein-apolipoprotein B metabolism following apheresis: simulation studies of mass changes and tracer kinetics. (1998) (12)
Effects of a cluster-randomized school-based prevention program on physical activity and microvascular function (JuvenTUM 3). (2018) (12)
Lipoprotein (a) and Low‐density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease (2018) (11)
Less Advanced Stages of Colon Cancer in Patients with Type 2 Diabetes Mellitus: an Unexpected Finding? (2012) (10)
How will new medications affect the lipoprotein apheresis situation in Germany? (2013) (10)
Risk Factors and Event Rates in Patients With Atherothrombotic Disease in Germany: Results of the REACH Registry. (2008) (9)
Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention. (2005) (9)
Autoimmune hypoglycemia presenting as seizure one week after surgery. (2001) (9)
Low density lipoprotein apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters. (1999) (9)
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. (2022) (9)
Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy. (2013) (8)
760 MIPOMERSEN AN APOB SYNTHESIS INHIBITOR EVALUATION OF POTENTIAL TO REDUCE NECESSITY FOR LIPID-APHERESIS IN PATIENTS WITH HETEROZYGOUS FH AND CAD (2011) (8)
Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus (2010) (8)
Hydrothermally modified slow release corn starch: a potential new therapeutic option for treating hypoglycemia in autoimmune hypoglycemia (Hirata’s disease) (2015) (8)
Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis. (2000) (8)
Simplified algorithm to facilitate communication of familial hypercholesterolaemia. (2015) (7)
Long-term LDL apheresis does not stably improve hemorheology in hypercholesterolemic patients with coronary artery disease. (2009) (7)
Novel mutation (Gly280Ala) in the ATP-binding domain of glycerol kinase causes severe hyperglycerolemia. (2005) (6)
Interferon-α-induced agranulocytosis in a patient on long-term clozapine therapy (1998) (6)
Prevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemia (2017) (6)
Irbesartan has no short‐term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i‐RESPOND) (2009) (6)
Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia. (2003) (6)
Extracorporal Low‐density Lipoprotein Elimination by Immunoadsorption (2003) (6)
Gestational diabetes in Turkmenistan: implementation of a screening program and first results (2014) (6)
Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia. (2015) (6)
Postprandial Lipid Metabolism in Normolipidemic Subjects and Patients with Mild to Moderate Hypertriglyceridemia: Effects of Test Meals Containing Saturated Fatty Acids, Mono-Unsaturated Fatty Acids, or Medium-Chain Fatty Acids (2021) (6)
11 Komplikationen und Monitoring (2007) (6)
Familial hypercholesterolemia--screening to facilitate early prevention. (2014) (5)
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap (2020) (5)
Comparison of automated insulin assays. (2007) (5)
Physical Activity and Outdoor Leisure Time Physical Exercise: A Population Study of Correlates and Hindrances in a Resource-Constrained African Setting (2020) (5)
Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats. (2019) (5)
[Clinical importance of HDL cholesterol]. (2017) (5)
[Effect of glucose control on lipid levels in patients with type 2 diabetes]. (2002) (5)
Suppression of the Nuclear Factor Eny2 Increases Insulin Secretion in Poorly Functioning INS-1E Insulinoma Cells (2012) (5)
BMI and hyperinsulinemia in children. (2009) (5)
Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia) (2022) (4)
Myocardial perfusion before and after single routine LDL-apheresis (1998) (4)
In Germany diabetic patients with coronary artery disease are treated more intensively than diabetic patients with other manifestations of atherothrombosis--results from the REACH registry. (2009) (4)
In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects. (2006) (4)
Postmenopausal estrogen and the metabolism of plasma lipoproteins. (1992) (4)
Impact of perceptions of body size on obesity and weight management behaviour: a large representative population study in an African setting. (2019) (4)
Optical Coherence Tomography to Assess Neurodegeneration in Phenylalanine Hydroxylase Deficiency (2021) (3)
THE EFFECT OF PCSK9 INHIBITION ON LDL-SUBFRACTIONS IN PATIENTS WITH SEVERE LDL-HYPERCHOLESTEROLEMIA (2017) (3)
Cisplatin-Based Chemotherapy for Pulmonary Metastasized Germ Cell Tumors of the Testis – Be Aware of Acute Respiratory Distress Syndrome (2009) (3)
Corrigendum to: "Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)" [Atherosclerosis 259 (2017 Apr) 20-25]. (2018) (3)
Head-to-head comparison of an automated immunometric and an automated HPLC method for the quantification of HbA1c. (2008) (3)
Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany (2022) (2)
Statin intolerance is the main indication for PCSK9 inhibition in clinical practice. (2017) (2)
Pcsk9-Inhibition In Routine Clinical Practice: Real World Data From Germany (2019) (2)
Effect of a high-fat meal on the postprandial ghrelin response. Authors' reply (2006) (2)
Lipoprotein metabolism in an apoB-80 familial hypobetalipoproteinemia heterozygote. (2016) (2)
4.P.255 Lipid and apolipoprotein composition of lipoproteins in hypocholesterolemia of sepsis (1997) (2)
Determinants of Outcome of Children with Type 1 Diabetes in Cameroon (2015) (2)
Everyday Life, Dietary Practices, and Health Conditions of Adult PKU Patients: A Multicenter, Cross-Sectional Study (2020) (2)
Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. (2019) (2)
In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy Published, JLR Papers in Press, June 1, 2004. DOI 10.1194/jlr.M300523-JLR200 (2004) (2)
Effect of cholecystectomy on bile acid metabolism and serum lipoprotein profiles (2000) (2)
Association of HDL deficiency with a novel mutation in the ABCA1 gene. (2010) (2)
PDB64 The Avoidance of Weight Gain is Important for Oral Type 2 Diabetes Treatments in Sweden and Germany: A Patient Preference Study (2012) (2)
[Update: clinical lipidology]. (2013) (2)
[Bariatric surgery from the internist's point of view]. (2010) (1)
[PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?]. (2016) (1)
The patient with CHD: how should we translate international guidelines into clinical practice? (2000) (1)
Differential effects of high fat diets on rat glucose and lipid metabolism (2005) (1)
New targets for treating hypertriglyceridemia (2022) (1)
CONTROVERSIAL ISSUES IN THE TREATMENT OF DYSLIPIDEMIAS IN PATIENTS WITH DIABETES MELLITUS. (2018) (1)
Lipoprotein(a) (2021) (1)
Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia (2022) (1)
[Dietary advice for preventing and treating T2DM: A shift of paradigm]. (2016) (1)
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements (2022) (1)
Screening for Gestational Diabetes Mellitus and Pregnancy Outcomes: Results from a Multicentric Study in Tajikistan (2022) (1)
2.P.143 Lipoprotein (a) metabolism in patients with heterozygous familial hypercholesterolemia (1997) (1)
P5382PEARL, a non-interventional study on real-world use of alirocumab in German clinical practice: final study and cardiovascular subgroup data (2018) (1)
Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia (2000) (1)
Lower diabetes rate in patients with familial hypercholesterolaemia: What is the link? (2020) (1)
The Other End of the Spectrum: Hypobetalipoproteinemia (1993) (1)
[25 years of progress in the treatment of metabolic disorders: statins revolutionise cardiovascular prevention]. (2008) (1)
Diabetes Update 2017 – Lipide (2017) (1)
Interferon-alpha-induced agranulocytosis in a patient on long-term clozapine therapy. (1998) (1)
[Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors]. (2001) (1)
THE EFFECT OF PCSK9 INHIBITION IN FAMILIAL DYSBETALIPOPROTEINEMIA (TYPE III HYPERLIPOPROTEINEMIA): 4 CASES (2018) (1)
[Cardio-vascular medicine: lipid goals]. (2019) (1)
Mo-P6:432 Genetic variants of adipor 2 are associated with increased adiponectin levels and decreased triglyceride/VLDL levels (2006) (1)
[Differentiated target values--differentiated treatment of lipid disorders. Diagnosis and treatment of diabetes are now on the move]. (2011) (1)
Serum biomarkers and retinal vessel diameters in school children (2013) (1)
Prävalenz des Gestationsdiabetes in Turkmenistan (2010) (1)
[Treatment of hyperlipidemia in the elderly]. (2008) (1)
Health sector readiness for the prevention and control of non-communicable diseases: A multi-method qualitative assessment in Nepal (2022) (1)
[After bypass surgery nearly all lipids are in the normal range. However, Lp(a) is too high, what can be done?]. (2011) (1)
Therapy and clinical trials. (2018) (0)
[Cushing's syndrome with bilateral nodular adrenal enlargement]. (2007) (0)
[Muscular symptoms associated with statin therapy]. (2023) (0)
Caloric restriction by diet or sleeve gastrectomy has little effect on metainflammation despite improving insulin resistance (2014) (0)
[Is cholesterol actually not so unhealthy?]. (2015) (0)
[Reduced bone density and bone pain :osteomalacia with hypophospatemia and hypophosphaturia]. (2009) (0)
[Increased plasma levels of vitamin B12]. (2021) (0)
Abstract: 1067 COMPARISON OF 2-YEAR EVENT RATES BETWEEN WESTERN AND EASTERN EUROPEAN DIABETICS WITH ESTABLISHED ATHEROTHROMBOSIS (RESULTS FROM THE REACH-REGISTRY) (2009) (0)
Interleukin 6, procalcitonin and CRP levels during first increase of fever in intensive care patients 1 (2008) (0)
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. (2023) (0)
[Statin plus niacin or ezetimibe? What combination for which patients?]. (2009) (0)
[Update dyslipidemia]. (2013) (0)
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study (2021) (0)
Effects of lipoprotein apheresis (la) on serum pcsk9 levels (2014) (0)
[Analysis of Secondary Data to Determine the Prevalence of Cardiovascular High Risk Patients with Hypercholesterolemia and Refractory Course of Treatment]. (2017) (0)
[Therapy of hyperlipoproteinemia in the elderly]. (2003) (0)
Influence of atorvastatin on LDL-subtypes in patients with hypertriglyceridemia (2001) (0)
Core Evidence Mipomersen : evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia (2012) (0)
Treatment of hypercholesterolemia. (1998) (0)
Abstract 625: Niacin Improves Atherogenic Postprandial Lipemia in Patients at High Cardiovascular Risk Despite Reduced Cholesterol Efflux From Human Macrophages (2014) (0)
[Diabetic dyslipoproteinemia]. (2006) (0)
[Update dyslipidemia]. (2016) (0)
Optical Coherence Tomography: Retinal Imaging Contributes to the Understanding of Brain Pathology in Classical Galactosemia (2023) (0)
[PCSK9 inhibitors: For which patients? For which indication? What to consider?] (2018) (0)
[Lower LDL and/or raise HDL. In what direction is lipidology moving?]. (2007) (0)
EFFECTS OF TWO WHOLE BLOOD SYSTEMS (DALI AND LIPOSORBER D) FOR LDL APHERESIS ON CARDIOVASCULAR RISK IN SEVERE HYPERCHOLESTEROLAEMIA (2008) (0)
Estimating Prevalence and Characteristics of Statin Intolerance among High and Very High Cardiovascular Risk Patients in Germany (2017 to 2020) (2023) (0)
[What's new in insulin treatment?]. (2004) (0)
[Incidental finding: hypertriglyceridemia]. (2020) (0)
Understanding lipoprotein(a) metabolism: Rebound analyses of lipoprotein(a) and PCSK9 concentrations following regular lipoprotein apheresis treatment (the Lipare-study) (2016) (0)
Phytosterols and Cardiovascular Risk Evaluated against the Background of Phytosterolemia Cases—A German Expert Panel Statement (2023) (0)
[Triglycerides - assessment as risk factor and therapeutic goals]. (2022) (0)
TRUNCATED FORMS OF APOLIPOPROTEIN-B AND HYPOBETALIPOPROTEINEMIA (1992) (0)
Incretin-based Therapy and the Prevention of Hypoglycaemia (2007) (0)
Performance Characteristics of Lipidfiltration for LDL-Apheresis: Intraindividual Comparison with Dextran- Sulfate-Adsorption and Influence of Anticoagulatory Regime (2004) (0)
Short-medium- and long-term effect of ursodeoxycholic acid on cholesterol an bile acid synthesis in healthy humans (2001) (0)
[Accidental finding: hypertriglyceridemia]. (2015) (0)
[Risk and benefits of hormone replacement therapy by postmenopausal women. WHI-Study]. (2003) (0)
Effect of atorvastatin on LDL subtype pattern and endothelial function (2001) (0)
W16-P-065 Influence of atorvastatin on myeloperoxidase levels in hypertriglycer idemic patients (2005) (0)
Die neuen Standards in der Diabetologie (2012) (0)
Effect of sleeve gastrectomy on postprandial lipoprotein metabolism in morbidly obese patients (2013) (0)
[Antidiabetic drug therapy in overweight and obese adults with type 2 diabetes]. (2013) (0)
In Reply. (2020) (0)
[Homozygous familial hypercholesterolemia]. (2023) (0)
Differentiating EPA from EPA/DHA in cardiovascular risk reduction (2022) (0)
Diabetes-Therapie à la carte (2017) (0)
Height-obesity relationship in school children in Sub-Saharan Africa: results of a cross-sectional study in Cameroon (2015) (0)
[Choosing Wisely in endocrinology]. (2022) (0)
[Secondary dyslipoproteinemia--genes and lifestyle are not always responsible for high cholesterol levels]. (2006) (0)
Social determinants and behaviors associated with overweight and obesity among youth and adults in a peri-urban area of Maputo City, Mozambique (2021) (0)
[Lipidology - important changes of the last 10 years]. (2018) (0)
METABOLIC PARAMETERS IN HEALTHY SCHOOL CHILDREN AGED 6-12 YEARS: THE PEP FAMILY HEART STUDY (2008) (0)
MS401 RANDOMIZED TRIAL OF LIPID APHERESIS IN PATIENTS WITH ELEVATED ISOLATED LIPOPROTEIN(a) CONCENTRATIONS: STUDY DESIGN OF THE ELAILa TRIAL (2010) (0)
PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 ADDRESSING DRUGS (2017) (0)
Over 30 years of elaborate experience in LDL apheresis: An effective and well-tolerated treatment option for specific patient subgroups (2020) (0)
Mechanisms of genetically-determined diabetes resistance and susceptibility in db/db mice (2010) (0)
Prevalence of the Metabolic Syndrome in Severely Obese Patients Presenting for Bariatric Surgery (2020) (0)
Peroxisome Proliferator-Activated Receptor ( PPAR ) High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-Target Genes in Patients With the Metabolic Syndrome (2011) (0)
PDB73 THE PANORAMA PAN-EUROPEAN SURVEY: HYPOGLYCAEMIA ASSOCIATED WITH DIFFERENT PHARMACOLOGICAL TREATMENTS FOR TYPE 2 DIABETES (2010) (0)
Impact of extended-release niacin on atherogenic triglyceride-rich lipoproteins during the postprandial phase in subjects at high cardiovascular risk (2014) (0)
In Reply. (2016) (0)
[Recognizing Chylomicronemia Syndrome]. (2022) (0)
The ODYSSEY ESCAPE study: rationale, design, patient characteristics at baseline, and final study data (2016) (0)
W16-P-030 Effect of ezetimibe on LDL-subtype distribution: Results of a placebo controlled trial in patients treated by regular LDL-apheresis and statins (2005) (0)
Abstract 4722: Association of Systemic Markers of Inflammation and Thrombogenity to Coronary Plaque Composition Determined by Contrast Enhanced Dual Source Ct- Angiography (2008) (0)
PCV60 TWO-YEAR HOSPITALIZATION RATES AND ASSOCIATED COSTS IN PATIENTS FROM GERMANY WITH PERIPHERAL ARTERIAL DISEASE: RESULTS FROMTHE REDUCTION OF AT HEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY (2008) (0)
Two years of pegvaliase in Germany: Experiences and best practice recommendations. (2023) (0)
[Therapy and risk assessment in dyslipidemia]. (2021) (0)
[Diabetology for the general practitioner: common questions and the answers of the experts]. (2014) (0)
Risk Factors and Event Rates in Patients With Atherothrombotic Disease in Germany (2008) (0)
Long-term costs of atherothrombotic disease burden in western Europe: Highest costs in peripheral arterial disease (2019) (0)
Atorvastatin increases the catabolism of chylomicron remnants in normolipidemic subjects (2000) (0)
[What is new in lipidology?] (2023) (0)
Anti‐PCSK 9 antibodies increase the ratios of the brain‐specific oxysterol 24S‐hydroxycholesterol to cholesterol and to 27‐hydroxycholesterol in the serum (2021) (0)
[Primary prevention in atherosclerosis. Properly assessing the risk of your patient]. (2001) (0)
WALNUT-ENRICHED DIET REDUCES LIPIDS IN HEALTHY CAUCASIAN SUBJECTS, INDEPENDENT OF RECOMMENDED MACRONUTRIENT REPLACEMENT (2017) (0)
Abstract 15055: Walnut-Enriched Diet Beneficially Alters Gut Microbiome in Healthy Caucasian Subjects (2017) (0)
Insulin resistance in women after pregnancy is associated with changes in the serum nonesterified fatty acid profile (2014) (0)
Therapy and clinical trials. (2018) (0)
Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020 (2022) (0)
[Diabetes mellitus: new standards]. (2012) (0)
[Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?]. (2008) (0)
Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study. (2022) (0)
Postmenopausal hormone therapy and cardiovascular disease. (2001) (0)
[Atherosclerosis: cholesterol efflux capacity: a new independent risk factor]. (2015) (0)
Acknowledgement to Reviewers (2016) (0)
Prevalence of Therapy-Resistant Hypercholesterolemia in High-Risk Cardiovascular Patients in Germany (2016) (0)
[Aspirin and statins for every diabetic?]. (2015) (0)
Too Many Competing Interests Reply (2016) (0)
[A 32-year old male patient with pathological humeral fracture, splenomegaly and thrombocytopenia]. (2004) (0)
[Increased plasma levels of prolactin]. (2021) (0)
[Incidental finding: increased cholesterol level]. (2010) (0)
2P-0591 Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia (2003) (0)
Predictors of glucose control in children and adolescents with type 1 diabetes: results of a cross-sectional study in Cameroon (2017) (0)
[Which patient will now actually benefit from ezetimib?]. (2014) (0)
Involvement of SNARE components in the transfer of cholesterol from lipid droplets to mitochondria in rat adrenals and ovaries (2015) (0)
German lipid clinic experience with adherence to PCSK-9-inhibitor therapy (2020) (0)
The German CaRe High Registry for Familial Hypercholesterolemia –Sex Differences, Treatment Strategies and Target Value Attainment (2022) (0)
[Treatment of diabetes mellitus: new findings lead to new recommendations]. (2016) (0)
[Not Available]. (2008) (0)
[Sequelae of the JUPITER study. What is changing in primary prevention? (interview by Dr. med. Dirk Einecke)]. (2008) (0)
Atorvastatin lowers plasma viscosity in patients with hypertriglyceridemia (2001) (0)
Consensus on Treatment Recommendations for Urogenital Infections in Type 2 Diabetics (2012) (0)
M.609 Effects of atorvastatin vs. fenofibrate on ghrelin levels in type 2 diabetic patients with mixed hyperlipoproteinemia (2004) (0)
Lipoprotein(a) concentrations and apolipoprotein-E isoforms (2015) (0)
Abstract 236: Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia (2014) (0)
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful? (2021) (0)
Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. (2022) (0)
Influence of LDL-apheresis on LDL-subspecies in patients with coronary heart disease (CHD) and severe LDL-hypercholesterolemia (1999) (0)
Abstract 14868: Effect of Apheresis on Alirocumab and PCSK9 Concentrations in the ODYSSEY ESCAPE Study (2017) (0)
[Lipidology update : Evidence-based treatment of dyslipidemia]. (2020) (0)
[Reducing blood sugar at the cost of increasing weight must be avoided]. (2013) (0)
[Glinides and glitazones in diabetes treatment. Are they really effective?]. (2002) (0)
Author ’ s response to reviews Title : Elevation of small , dense low density lipoprotein cholesterol — a possible antecedent of atherogenic lipoprotein phenotype in type 2 diabetes patients in Jos , North-Central Nigeria (2017) (0)
DGEM guidelines enteral nutrition: Diabetes mellitus (2003) (0)
Abstract 10859: Walnut-enriched Diet Reduces Fasting Non-HDL-cholesterol in Healthy Caucasian Subjects (2012) (0)
M.519 LDL-apheresis by lipid filtration in patients with severe hypercholesterolemia and coronary heart disease: Effect of two different anticoagulation methods and comparison with dextran sulfate adsorption (2004) (0)
[Statines for all or individualized lipid lowering therapy?]. (2009) (0)
Reply to: "Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study". (2018) (0)
MMP-1 serum levels predict non-calcified atherosclerotic plaques (2009) (0)
The mechanisms of improved glucose metabolism after weight reduction in morbidly obese patients with type 2 diabetes mellitus : effects of a diet simulating the situation after baiatric surgery (2013) (0)
[The role of insulin therapy in type 2 diabetes--current standards and recommendations]. (2012) (0)
Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia due to truncated apolipoprotein B variants (2005) (0)
Essentials of Familial Hypercholesterolemia (2014) (0)
[Diabetic dyslipoproteinemia]. (2011) (0)
From the EAS:* frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society (2023) (0)
Effects of atorvastatin vs. fenofibrate on lipoproteins, LDL-subfraction distribution and hemorheology in type 2 diabetic patients with mixed hyperlipoproteinemia (2000) (0)
M.520 Effect of additional ezetimibe or placebo on plasma lipoproteins in patients treated by regular LDL-apheresis and statins because of severe hyperlipoproteinemia and coronary heart disease (2004) (0)
Physical Activity Measured by Pedometer in a Peri-Urban Mozambican Population. (2022) (0)
Diabetes: Hit hard and early, please! (2019) (0)
Apheresis: What Should a Clinician Know? (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Klaus Georg Parhofer?

Klaus Georg Parhofer is affiliated with the following schools:

Ludwig Maximilian University of Munich

Klaus Georg Parhofer's Academic­Influence.com Rankings

Why Is Klaus Georg Parhofer Influential?

Klaus Georg Parhofer's Published Works

Published Works

What Schools Are Affiliated With Klaus Georg Parhofer?

Klaus Georg Parhofer's AcademicInfluence.com Rankings